A federal court formally approved a $7.25 billion class settlement for claims linking Roundup weed killer to cancer, marking a major step toward resolving litigation that has shadowed Bayer since its 2018 acquisition of Monsanto.
The settlement addresses cancer claims from individuals who allege they developed non-Hodgkin lymphoma after exposure to Roundup. The class action mechanism allows thousands of claimants to resolve their cases collectively, avoiding individual trials.
Bayer said it continues to stand by Roundup's safety, maintaining that decades of studies show glyphosate, the active ingredient, is safe when applied as directed.
The $7.25 billion commitment represents a substantial financial toll from the litigation that has dogged the company since the Monsanto purchase. The settlement aims to end years of legal battles that have damaged Bayer's financial performance and reputation.
